1. Introduction: A Systemic Therapy with Two Curative Logics
Hematopoietic stem cell transplantation (HSCT) is the most aggressive systemic treatment in oncology. It has two distinct rationales. In autologous transplantation, the patient’s own stem cells are collected, high-dose chemotherapy (with or without radiation) is given to eradicate the cancer, and the cells are returned to rescue the bone marrow. In allogeneic transplantation, stem cells from a donor are given, exploiting not only dose intensification but also an immunological graft-versus-tumor effect. HSCT is curative in several hematologic malignancies and remains a benchmark against which cellular therapies such as CAR-T are measured.
2. Biological Rationale
The dose–response relationship in hematologic cancers is steep, and the bone marrow is the dose-limiting organ for most cytotoxic agents. HSCT circumvents that limit by rescuing hematopoiesis after myeloablative therapy. In allogeneic HSCT, the donor immune system provides a second, potentially durable therapeutic mechanism: donor T cells recognize recipient (and tumor) histocompatibility and tumor-associated antigens, producing graft-versus-leukemia or graft-versus-tumor effects. This is demonstrated by the reduced relapse risk in patients who develop graft-versus-host disease (GVHD) and by the effectiveness of donor lymphocyte infusions in relapsed disease.
3. Types and Techniques
| Dimension | Options |
|---|---|
| Graft source | Autologous; allogeneic (matched sibling, matched unrelated donor, haploidentical, umbilical cord) |
| Cell product | Peripheral blood stem cells; bone marrow; cord blood |
| Conditioning intensity | Myeloablative; reduced-intensity conditioning (RIC); non-myeloablative |
| Rationale | Dose intensification (autologous); dose intensification plus immune graft-versus-tumor effect (allogeneic) |
Peripheral blood stem cells, mobilized with growth factors or agents such as plerixafor, have largely replaced bone marrow as the graft source because of faster engraftment, though chronic GVHD rates may differ. Reduced-intensity conditioning has extended allogeneic transplantation to older and less fit patients by reducing early treatment-related mortality while preserving the graft-versus-tumor effect.
4. Confirmed Clinical Evidence
4.1. Multiple Myeloma
High-dose therapy with autologous stem cell rescue became a standard of care for eligible patients with multiple myeloma after a randomized trial by Attal and colleagues (Intergroupe Français du Myélome) showed improved response rates and survival compared with conventional chemotherapy. Modern myeloma therapy has added proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies, but autologous transplantation remains a standard consolidation approach for eligible patients.
4.2. Lymphomas
High-dose therapy with autologous transplant is established for relapsed, chemotherapy-sensitive aggressive lymphomas, including diffuse large B-cell lymphoma and Hodgkin lymphoma, based on randomized trials demonstrating improved outcomes compared with salvage chemotherapy alone. Allogeneic transplant is used in selected high-risk or multiply relapsed cases, exploiting the graft-versus-lymphoma effect.
4.3. Leukemias and Bone Marrow Failure
Allogeneic transplantation remains a curative option for high-risk acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia in appropriate phases, and for severe aplastic anemia in younger patients with a suitable donor. For acute promyelocytic leukemia, transplantation has largely been displaced by highly effective non-transplant therapy (see the companion article on differentiation therapy).
5. Early Research and Emerging Approaches
- Haploidentical transplantation with post-transplant cyclophosphamide has greatly expanded donor availability and is now widely used; comparative research on its long-term outcomes continues.
- Genetically modified grafts (for example, suicide-gene or CAR-expressing cells) aim to separate graft-versus-tumor activity from GVHD; this is early-stage research.
- Post-transplant maintenance with targeted agents (for example, in FLT3-mutant AML) has improved outcomes and is being refined.
6. Toxicity and Limitations
HSCT carries substantial risk. Early complications include infections during neutropenia, sinusoidal obstruction syndrome (veno-occlusive disease), and organ toxicity from conditioning. GVHD — acute and chronic — is the principal immunological complication of allogeneic transplantation and a major cause of morbidity and mortality. Long-term effects include infertility, endocrine dysfunction, chronic organ damage, and secondary malignancies. Treatment-related mortality, although declining, remains the reason transplantation is restricted to patients with a favorable risk–benefit balance and adequate organ function.
7. Unresolved Questions and Speculative Directions
- How HSCT will be positioned as CAR-T and bispecific antibodies mature — as an earlier or later option, or selectively — is not settled and depends on disease and setting.
- Whether precision graft engineering can reliably prevent GVHD without losing graft-versus-tumor activity remains an open research goal. [Marked for verification.]
8. Conclusion
Hematopoietic stem cell transplantation is a potent, potentially curative therapy based on dose intensification and, for allogeneic grafts, immunological graft-versus-tumor effects. It is established in multiple myeloma, relapsed lymphomas, high-risk leukemias, and aplastic anemia. Its costs are high — treatment-related mortality, GVHD, infections, and long-term organ and fertility effects — so patient selection is central. The field continues to evolve through reduced-intensity conditioning, haploidentical approaches, and graft engineering, while newer cellular immunotherapies are reshaping where transplantation fits.
Sources and Key Research Centers
- National Cancer Institute — stem cell transplant overviews.
- Center for International Blood and Marrow Transplant Research (CIBMTR) — registry outcomes data.
- European Society for Blood and Marrow Transplantation (EBMT) — European activity and outcome data.
- Autologous transplant in multiple myeloma
- Attal M, Harousseau JL, Stoppa AM, et al. «A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma.» New England Journal of Medicine, 1996; 335(2): 91–97. [Citation details to be verified.]
- Peripheral blood vs bone marrow grafts
- Schmitz N, Bacigalupo A, Hasenclever D, et al. «Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia.» The Lancet, 1998. [Citation details to be verified.]
- Reduced-intensity conditioning — cooperative-group and registry studies of RIC allografts in older patients. [Citation details to be verified.]
- ClinicalTrials.gov — ongoing trials of haploidentical transplant, graft engineering, and post-transplant maintenance (search terms: haploidentical transplant, reduced intensity conditioning).
Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.